• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用交互式平台对免疫相关不良结局途径进行编码、管理和探索。

Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways.

作者信息

Mazein Alexander, Shoaib Muhammad, Alb Miriam, Sakellariou Christina, Sommer Charline, Sewald Katherina, Reiche Kristin, Gogesch Patricia, Roser Luise A, Ortega Iannazzo Samira, Sheth Sapna, Schiffmann Susanne, Waibler Zoe, Neuhaus Vanessa, Dehmel Susann, Satagopam Venkata, Schneider Reinhard, Ostaszewski Marek, Gu Wei

机构信息

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.

Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Lehrstuhl für Zelluläre Immuntherapie, Würzburg, Germany.

出版信息

J Immunotoxicol. 2024 Oct;21(sup1):S5-S12. doi: 10.1080/1547691X.2024.2345154. Epub 2024 Dec 10.

DOI:10.1080/1547691X.2024.2345154
PMID:39655493
Abstract

This work focuses on the need for modeling and predicting adverse outcomes in immunotoxicology to improve nonclinical assessments of the safety of immunomodulatory therapies. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is illustrated with chimeric antigen receptor (CAR) T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed, and explored to benefit the research community. The map is accessible online at https://imsavar.elixir-luxembourg.org the MINERVA Platform for browsing, commenting, and data visualization. Our work transforms a graphical illustration of an AOP into a digitally structured and standardized form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.

摘要

这项工作聚焦于免疫毒理学中对不良后果进行建模和预测的需求,以改进免疫调节疗法安全性的非临床评估。该综合方法首先包括毒理学领域确立的不良后果途径概念,其次包括用于描述特定病理学中所涉及分子机制的系统医学疾病图谱方法。以嵌合抗原受体(CAR)T细胞治疗作为实例,对所提出的系统免疫毒理学工作流程进行了说明。为此,将线性不良后果途径(AOP)扩展为标准系统生物学格式的分子相互作用模型。然后展示了如何整合、编码、管理和探索与免疫毒性事件相关的知识,以使研究界受益。该图谱可在https://imsavar.elixir-luxembourg.org(MINERVA平台)在线获取,用于浏览、评论和数据可视化。我们的工作将AOP的图形说明转化为数字结构化和标准化形式,具有精确且可控的词汇表,并支持可重复的计算分析。由于对源文献和数据库进行了注释,该图谱可进一步扩展以匹配不断发展的知识和研究问题。

相似文献

1
Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways.利用交互式平台对免疫相关不良结局途径进行编码、管理和探索。
J Immunotoxicol. 2024 Oct;21(sup1):S5-S12. doi: 10.1080/1547691X.2024.2345154. Epub 2024 Dec 10.
2
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.基于不良结局途径概念评估嵌合抗原受体T细胞介导的细胞因子释放的新策略。
J Immunotoxicol. 2024 Oct;21(sup1):S13-S28. doi: 10.1080/1547691X.2024.2345158. Epub 2024 Dec 10.
3
An overview of immune safety avatar: mimicking the effects of immunomodulatory therapies on the immune system.
J Immunotoxicol. 2024 Oct;21(sup1):S1-S4. doi: 10.1080/1547691X.2024.2354213. Epub 2024 Dec 10.
4
Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach.解析嵌合抗原受体 T 细胞治疗中的肿瘤免疫景观:系统免疫学方法的关键挑战与机遇。
Clin Cancer Res. 2020 Jul 15;26(14):3505-3513. doi: 10.1158/1078-0432.CCR-19-3888. Epub 2020 Mar 3.
5
Mapping physiology: A systems biology approach for the development of alternative methods in toxicology.生理学映射:一种用于毒理学替代方法开发的系统生物学方法。
ALTEX. 2025;42(2):301-307. doi: 10.14573/altex.2412241. Epub 2025 Jan 20.
6
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞治疗 B 细胞急性淋巴细胞白血病。
Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018.
7
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.托西珠单抗治疗嵌合抗原受体 T 细胞引起的细胞因子释放综合征。
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. doi: 10.1080/1744666X.2019.1629904. Epub 2019 Jun 20.
8
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.嵌合抗原受体 T 细胞治疗中细胞因子释放综合征的特征和危险因素。
Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021.
9
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.第四代抗 CD19 嵌合抗原受体 T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期临床试验。
Front Immunol. 2020 Nov 27;11:564099. doi: 10.3389/fimmu.2020.564099. eCollection 2020.
10
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪:CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.

引用本文的文献

1
An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies.与免疫调节生物疗法和细胞疗法给药相关的细胞因子释放综合征不良结局途径的可探索模型。
Front Immunol. 2025 Aug 8;16:1601670. doi: 10.3389/fimmu.2025.1601670. eCollection 2025.
2
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.工程化过继性细胞免疫疗法中生物医学虚拟孪生体的设计规范。
NPJ Digit Med. 2025 Aug 1;8(1):493. doi: 10.1038/s41746-025-01809-6.